How personal loss and hope drove Elaine Maynard’s work in clinical trials and patient-centric technologies

Citius Pharma receives FDA approval for immunotherapy targeting rare blood cancer

Halda Therapeutics raises $126M to take 'hold and kill' precision cancer drugs to the clinic

Gilead gains accelerated FDA approval for rare liver disease treatment

FDA lifts hold on BioNTech and MediLink's ADC trial After safety revisions

Breakthrough delivery system could transform Alzheimer’s treatment

First bispecific CAR-T therapy for MS receives green light from FDA to start phase 1

Breaking News: Lecanemab approved in UK but unavailable on NHS

Highlights

array(40) {
  [0]=>
  string(4) "2505"
  ["article_id"]=>
  string(4) "2505"
  [1]=>
  string(46) "Canada Details New User Fees for Drug Sponsors"
  ["article_title"]=>
  string(46) "Canada Details New User Fees for Drug Sponsors"
  [2]=>
  string(153) "&#nl        Health Canada is increasing fees for drug sponsors and will peg ongoing increases to inflation, the agency said in a final report on the plan"
  ["short_description"]=>
  string(153) "&#nl        Health Canada is increasing fees for drug sponsors and will peg ongoing increases to inflation, the agency said in a final report on the plan"
  [3]=>
  string(175) "&#nl        Health Canada is increasing fees for drug sponsors and will peg ongoing increases to inflation, the agency said in a final report on the planned changes.&#nl      "
  ["description"]=>
  string(175) "&#nl        Health Canada is increasing fees for drug sponsors and will peg ongoing increases to inflation, the agency said in a final report on the planned changes.&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "16"
  ["rss_id"]=>
  string(2) "16"
  [14]=>
  string(86) "https://www.fdanews.com/articles/191345-canada-details-new-user-fees-for-drug-sponsors"
  ["blog_url"]=>
  string(86) "https://www.fdanews.com/articles/191345-canada-details-new-user-fees-for-drug-sponsors"
  [15]=>
  string(19) "2019-05-18 05:27:25"
  ["add_date"]=>
  string(19) "2019-05-18 05:27:25"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:18:36"
  ["create_at"]=>
  string(19) "2019-05-23 14:18:36"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Canada Details New User Fees for Drug Sponsors

&#nl Health Canada is increasing fees for drug sponsors and will peg ongoing increases to inflation, the agency s

array(40) {
  [0]=>
  string(4) "2607"
  ["article_id"]=>
  string(4) "2607"
  [1]=>
  string(73) "Eiger Bio’s Apelian Gives Notice, Takes CEO Job at Private Biotech"
  ["article_title"]=>
  string(73) "Eiger Bio’s Apelian Gives Notice, Takes CEO Job at Private Biotech"
  [2]=>
  string(150) "David Apelian, chief operating officer and executive medical officer at Eiger BioPharmaceuticals (NASDAQ: EIGR) for the past 17 months, is stepping do"
  ["short_description"]=>
  string(150) "David Apelian, chief operating officer and executive medical officer at Eiger BioPharmaceuticals (NASDAQ: EIGR) for the past 17 months, is stepping do"
  [3]=>
  string(349) "David Apelian, chief operating officer and executive medical officer at Eiger BioPharmaceuticals (NASDAQ: EIGR) for the past 17 months, is stepping down. The Palo Alto, CA, drug developer said Friday that Apelian accepted an offer to become CEO of an unnamed private biotech company. Apelian, whose last day will be June 14, will remain on […]"
  ["description"]=>
  string(349) "David Apelian, chief operating officer and executive medical officer at Eiger BioPharmaceuticals (NASDAQ: EIGR) for the past 17 months, is stepping down. The Palo Alto, CA, drug developer said Friday that Apelian accepted an offer to become CEO of an unnamed private biotech company. Apelian, whose last day will be June 14, will remain on […]"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "36"
  ["rss_id"]=>
  string(2) "36"
  [14]=>
  string(110) "https://xconomy.com/san-francisco/2019/05/17/eiger-bios-apelian-gives-notice-takes-ceo-job-at-private-biotech/"
  ["blog_url"]=>
  string(110) "https://xconomy.com/san-francisco/2019/05/17/eiger-bios-apelian-gives-notice-takes-ceo-job-at-private-biotech/"
  [15]=>
  string(19) "2019-05-18 05:21:20"
  ["add_date"]=>
  string(19) "2019-05-18 05:21:20"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:24:09"
  ["create_at"]=>
  string(19) "2019-05-23 14:24:09"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Eiger Bio’s Apelian Gives Notice, Takes CEO Job at Private Biotech

David Apelian, chief operating officer and executive medical officer at Eiger BioPharmaceuticals (NASDAQ: EIGR) for the 

array(40) {
  [0]=>
  string(4) "2608"
  ["article_id"]=>
  string(4) "2608"
  [1]=>
  string(67) "San Diego Life Sciences Roundup: MedCrypt, LunaDNA, Dynacure & More"
  ["article_title"]=>
  string(67) "San Diego Life Sciences Roundup: MedCrypt, LunaDNA, Dynacure & More"
  [2]=>
  string(155) "Let’s catch up with the latest life sciences news in San Diego. — Cybersecurity company MedCrypt, which makes software to protect medical devi"
  ["short_description"]=>
  string(155) "Let’s catch up with the latest life sciences news in San Diego. — Cybersecurity company MedCrypt, which makes software to protect medical devi"
  [3]=>
  string(362) "Let’s catch up with the latest life sciences news in San Diego. — Cybersecurity company MedCrypt, which makes software to protect medical devices, raised a $5.3 million Series A funding round. The company says it will use the new funds to hire new salespeople and engineers and further develop its technology, which medical devices vendors […]"
  ["description"]=>
  string(362) "Let’s catch up with the latest life sciences news in San Diego. — Cybersecurity company MedCrypt, which makes software to protect medical devices, raised a $5.3 million Series A funding round. The company says it will use the new funds to hire new salespeople and engineers and further develop its technology, which medical devices vendors […]"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "36"
  ["rss_id"]=>
  string(2) "36"
  [14]=>
  string(104) "https://xconomy.com/san-diego/2019/05/17/san-diego-life-sciences-roundup-medcrypt-lunadna-dynacure-more/"
  ["blog_url"]=>
  string(104) "https://xconomy.com/san-diego/2019/05/17/san-diego-life-sciences-roundup-medcrypt-lunadna-dynacure-more/"
  [15]=>
  string(19) "2019-05-18 05:17:09"
  ["add_date"]=>
  string(19) "2019-05-18 05:17:09"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:24:09"
  ["create_at"]=>
  string(19) "2019-05-23 14:24:09"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

San Diego Life Sciences Roundup: MedCrypt, LunaDNA, Dynacure & More

Let’s catch up with the latest life sciences news in San Diego. — Cybersecurity company MedCrypt, which mak

array(40) {
  [0]=>
  string(4) "2788"
  ["article_id"]=>
  string(4) "2788"
  [1]=>
  string(68) "FDA Issues Warning About Unauthorized Diabetes Management Devices"
  ["article_title"]=>
  string(68) "FDA Issues Warning About Unauthorized Diabetes Management Devices"
  [2]=>
  string(153) "The use of such devices could result in patient injury or even death.&#nlThe post FDA Issues Warning About Unauthorized Diabetes Management Devices "
  ["short_description"]=>
  string(153) "The use of such devices could result in patient injury or even death.&#nlThe post FDA Issues Warning About Unauthorized Diabetes Management Devices "
  [3]=>
  string(452) "
The use of such devices could result in patient injury or even death.
&#nl
The post FDA Issues Warning About Unauthorized Diabetes Management Devices appeared first on MedTech Intelligence.
&#nl"
  ["description"]=>
  string(452) "
The use of such devices could result in patient injury or even death.
&#nl
The post FDA Issues Warning About Unauthorized Diabetes Management Devices appeared first on MedTech Intelligence.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "98"
  ["rss_id"]=>
  string(2) "98"
  [14]=>
  string(115) "https://www.medtechintelligence.com/news_article/fda-issues-warning-about-unauthorized-diabetes-management-devices/"
  ["blog_url"]=>
  string(115) "https://www.medtechintelligence.com/news_article/fda-issues-warning-about-unauthorized-diabetes-management-devices/"
  [15]=>
  string(19) "2019-05-18 01:39:48"
  ["add_date"]=>
  string(19) "2019-05-18 01:39:48"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:25:07"
  ["create_at"]=>
  string(19) "2019-05-23 14:25:07"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

FDA Issues Warning About Unauthorized Diabetes Management Devices

The use of such devices could result in patient injury or even death.

&#nl

The post 

array(40) {
  [0]=>
  string(4) "2525"
  ["article_id"]=>
  string(4) "2525"
  [1]=>
  string(116) "Oxford Immunotec Welcomes Updated CDC Recommendations for Tuberculosis Screening and Testing of Healthcare Personnel"
  ["article_title"]=>
  string(116) "Oxford Immunotec Welcomes Updated CDC Recommendations for Tuberculosis Screening and Testing of Healthcare Personnel"
  [2]=>
  string(158) "OXFORD, United Kingdom and MARLBOROUGH, Mass., May  17, 2019  (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global,"
  ["short_description"]=>
  string(158) "OXFORD, United Kingdom and MARLBOROUGH, Mass., May  17, 2019  (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global,"
  [3]=>
  string(703) "
OXFORD, United Kingdom and MARLBOROUGH, Mass., May  17, 2019  (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that it welcomes the updated Tuberculosis Screening, Testing, and Treatment of U.S. Health Care Personnel: Recommendations from the National Tuberculosis Controllers Association and CDC, 2019, published by the U.S. Centers for Disease Control and Prevention (CDC)1. These guidelines increase the focus on eradicating tuberculosis (TB) disease in the United States through an individual risk-based approach to screening and treatment for Healthcare Personnel (HCP).
"
  ["description"]=>
  string(703) "
OXFORD, United Kingdom and MARLBOROUGH, Mass., May  17, 2019  (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that it welcomes the updated Tuberculosis Screening, Testing, and Treatment of U.S. Health Care Personnel: Recommendations from the National Tuberculosis Controllers Association and CDC, 2019, published by the U.S. Centers for Disease Control and Prevention (CDC)1. These guidelines increase the focus on eradicating tuberculosis (TB) disease in the United States through an individual risk-based approach to screening and treatment for Healthcare Personnel (HCP).
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "26"
  ["rss_id"]=>
  string(2) "26"
  [14]=>
  string(187) "http://www.globenewswire.com/news-release/2019/05/17/1826920/0/en/Oxford-Immunotec-Welcomes-Updated-CDC-Recommendations-for-Tuberculosis-Screening-and-Testing-of-Healthcare-Personnel.html"
  ["blog_url"]=>
  string(187) "http://www.globenewswire.com/news-release/2019/05/17/1826920/0/en/Oxford-Immunotec-Welcomes-Updated-CDC-Recommendations-for-Tuberculosis-Screening-and-Testing-of-Healthcare-Personnel.html"
  [15]=>
  string(19) "2019-05-17 21:25:00"
  ["add_date"]=>
  string(19) "2019-05-17 21:25:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:23:48"
  ["create_at"]=>
  string(19) "2019-05-23 14:23:48"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Oxford Immunotec Welcomes Updated CDC Recommendations for Tuberculosis Screening and Testi

OXFORD, United Kingdom and MARLBOROUGH, Mass., May 17, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq

array(40) {
  [0]=>
  string(4) "2636"
  ["article_id"]=>
  string(4) "2636"
  [1]=>
  string(48) "Adalimumab biosimilar Idacio launched in Germany"
  ["article_title"]=>
  string(48) "Adalimumab biosimilar Idacio launched in Germany"
  [2]=>
  string(150) "Fresenius Kabi, one of the independently operated business segments of global healthcare group Fresenius, announced on 3 May 2019 that it had launched"
  ["short_description"]=>
  string(150) "Fresenius Kabi, one of the independently operated business segments of global healthcare group Fresenius, announced on 3 May 2019 that it had launched"
  [3]=>
  string(202) "
Fresenius Kabi, one of the independently operated business segments of global healthcare group Fresenius, announced on 3 May 2019 that it had launched its adalimumab biosimilar Idacio in Germany.
"
  ["description"]=>
  string(202) "
Fresenius Kabi, one of the independently operated business segments of global healthcare group Fresenius, announced on 3 May 2019 that it had launched its adalimumab biosimilar Idacio in Germany.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "42"
  ["rss_id"]=>
  string(2) "42"
  [14]=>
  string(92) "http://www.gabionline.net//Biosimilars/News/Adalimumab-biosimilar-Idacio-launched-in-Germany"
  ["blog_url"]=>
  string(92) "http://www.gabionline.net//Biosimilars/News/Adalimumab-biosimilar-Idacio-launched-in-Germany"
  [15]=>
  string(19) "2019-05-17 19:25:20"
  ["add_date"]=>
  string(19) "2019-05-17 19:25:20"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:24:21"
  ["create_at"]=>
  string(19) "2019-05-23 14:24:21"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Adalimumab biosimilar Idacio launched in Germany

Fresenius Kabi, one of the independently operated business segments of global healthcare group Fresenius, announced o

array(40) {
  [0]=>
  string(4) "2637"
  ["article_id"]=>
  string(4) "2637"
  [1]=>
  string(49) "ASCO/ASH give recommendations for biosimilar ESAs"
  ["article_title"]=>
  string(49) "ASCO/ASH give recommendations for biosimilar ESAs"
  [2]=>
  string(150) "Recommendations for biosimilar erythropoiesis-stimulating agents (ESAs) in the management of cancer-associated anaemia have been issued by the America"
  ["short_description"]=>
  string(150) "Recommendations for biosimilar erythropoiesis-stimulating agents (ESAs) in the management of cancer-associated anaemia have been issued by the America"
  [3]=>
  string(240) "
Recommendations for biosimilar erythropoiesis-stimulating agents (ESAs) in the management of cancer-associated anaemia have been issued by the American Society of Clinical Oncology (ASCO) and the American Society of Hematology (ASH).
"
  ["description"]=>
  string(240) "
Recommendations for biosimilar erythropoiesis-stimulating agents (ESAs) in the management of cancer-associated anaemia have been issued by the American Society of Clinical Oncology (ASCO) and the American Society of Hematology (ASH).
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "42"
  ["rss_id"]=>
  string(2) "42"
  [14]=>
  string(97) "http://www.gabionline.net//Biosimilars/Research/ASCO-ASH-give-recommendations-for-biosimilar-ESAs"
  ["blog_url"]=>
  string(97) "http://www.gabionline.net//Biosimilars/Research/ASCO-ASH-give-recommendations-for-biosimilar-ESAs"
  [15]=>
  string(19) "2019-05-17 19:22:04"
  ["add_date"]=>
  string(19) "2019-05-17 19:22:04"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:24:21"
  ["create_at"]=>
  string(19) "2019-05-23 14:24:21"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

ASCO/ASH give recommendations for biosimilar ESAs

Recommendations for biosimilar erythropoiesis-stimulating agents (ESAs) in the management of cancer-associated anaemi

array(40) {
  [0]=>
  string(4) "2638"
  ["article_id"]=>
  string(4) "2638"
  [1]=>
  string(68) "Alvotech signs agreement for ustekinumab biosimilar Stelara in Japan"
  ["article_title"]=>
  string(68) "Alvotech signs agreement for ustekinumab biosimilar Stelara in Japan"
  [2]=>
  string(150) "Iceland-based biopharmaceutical company Alvotech and Japan-based Fuji Pharma announced on 9 April 2019 that they had made a binding agreement for the "
  ["short_description"]=>
  string(150) "Iceland-based biopharmaceutical company Alvotech and Japan-based Fuji Pharma announced on 9 April 2019 that they had made a binding agreement for the "
  [3]=>
  string(267) "
Iceland-based biopharmaceutical company Alvotech and Japan-based Fuji Pharma announced on 9 April 2019 that they had made a binding agreement for the exclusive partnership and supply to commercialize Alvotech’s ustekinumab biosimilar, Stelara, in Japan.
"
  ["description"]=>
  string(267) "
Iceland-based biopharmaceutical company Alvotech and Japan-based Fuji Pharma announced on 9 April 2019 that they had made a binding agreement for the exclusive partnership and supply to commercialize Alvotech’s ustekinumab biosimilar, Stelara, in Japan.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "42"
  ["rss_id"]=>
  string(2) "42"
  [14]=>
  string(107) "http://www.gabionline.net//Pharma-News/Alvotech-signs-agreement-for-ustekinumab-biosimilar-Stelara-in-Japan"
  ["blog_url"]=>
  string(107) "http://www.gabionline.net//Pharma-News/Alvotech-signs-agreement-for-ustekinumab-biosimilar-Stelara-in-Japan"
  [15]=>
  string(19) "2019-05-17 19:17:11"
  ["add_date"]=>
  string(19) "2019-05-17 19:17:11"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:24:21"
  ["create_at"]=>
  string(19) "2019-05-23 14:24:21"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Alvotech signs agreement for ustekinumab biosimilar Stelara in Japan

Iceland-based biopharmaceutical company Alvotech and Japan-based Fuji Pharma announced on 9 April 2019 that they had 

array(40) {
  [0]=>
  string(4) "2526"
  ["article_id"]=>
  string(4) "2526"
  [1]=>
  string(122) "Terveystalo's network of occupational health services to expand: Terveystalo to acquire Työsyke Oy in Kanta-Häme"
  ["article_title"]=>
  string(122) "Terveystalo's network of occupational health services to expand: Terveystalo to acquire Työsyke Oy in Kanta-Häme"
  [2]=>
  string(25) "Press release 17 May 2019"
  ["short_description"]=>
  string(25) "Press release 17 May 2019"
  [3]=>
  string(36) "
Press release 17 May 2019
"
  ["description"]=>
  string(36) "
Press release 17 May 2019
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "26"
  ["rss_id"]=>
  string(2) "26"
  [14]=>
  string(192) "http://www.globenewswire.com/news-release/2019/05/17/1826768/0/en/Terveystalo-s-network-of-occupational-health-services-to-expand-Terveystalo-to-acquire-Ty%C3%B6syke-Oy-in-Kanta-H%C3%A4me.html"
  ["blog_url"]=>
  string(192) "http://www.globenewswire.com/news-release/2019/05/17/1826768/0/en/Terveystalo-s-network-of-occupational-health-services-to-expand-Terveystalo-to-acquire-Ty%C3%B6syke-Oy-in-Kanta-H%C3%A4me.html"
  [15]=>
  string(19) "2019-05-17 18:00:00"
  ["add_date"]=>
  string(19) "2019-05-17 18:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:23:48"
  ["create_at"]=>
  string(19) "2019-05-23 14:23:48"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Terveystalo's network of occupational health services to expand: Terveystalo to acquir

Press release 17 May 2019

array(40) {
  [0]=>
  string(4) "2900"
  ["article_id"]=>
  string(4) "2900"
  [1]=>
  string(159) "AbbVie Provides Update on Depatuxizumab Mafodotin (Depatux-M), an Investigational Medicine for Newly Diagnosed Glioblastoma, an Aggressive Form of Brain Cancer"
  ["article_title"]=>
  string(159) "AbbVie Provides Update on Depatuxizumab Mafodotin (Depatux-M), an Investigational Medicine for Newly Diagnosed Glioblastoma, an Aggressive Form of Brain Cancer"
  [2]=>
  string(150) "NORTH CHICAGO, Ill., May 17, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the Phase 3 "
  ["short_description"]=>
  string(150) "NORTH CHICAGO, Ill., May 17, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the Phase 3 "
  [3]=>
  string(251) "NORTH CHICAGO, Ill., May 17, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the Phase 3 INTELLANCE-1 study of depatuxizumab mafodotin (Depatux-M, previously known as ABT-414) in patients..."
  ["description"]=>
  string(251) "NORTH CHICAGO, Ill., May 17, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the Phase 3 INTELLANCE-1 study of depatuxizumab mafodotin (Depatux-M, previously known as ABT-414) in patients..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(300) "https://www.drugs.com/clinical_trials/abbvie-provides-update-depatuxizumab-mafodotin-depatux-m-investigational-medicine-newly-diagnosed-18157.html?utm_source=ddc&utm_medium=rss&utm_campaign=AbbVie+Provides+Update+on+Depatuxizumab+Mafodotin+%28Depatux-M%29%2C+an+Investigational+Medicine+for+Newly+Dia"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/clinical_trials/abbvie-provides-update-depatuxizumab-mafodotin-depatux-m-investigational-medicine-newly-diagnosed-18157.html?utm_source=ddc&utm_medium=rss&utm_campaign=AbbVie+Provides+Update+on+Depatuxizumab+Mafodotin+%28Depatux-M%29%2C+an+Investigational+Medicine+for+Newly+Dia"
  [15]=>
  string(19) "2019-05-17 14:05:24"
  ["add_date"]=>
  string(19) "2019-05-17 14:05:24"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-06-09 21:52:14"
  ["create_at"]=>
  string(19) "2019-06-09 21:52:14"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

AbbVie Provides Update on Depatuxizumab Mafodotin (Depatux-M), an Investigational Medicine

NORTH CHICAGO, Ill., May 17, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company

array(40) {
  [0]=>
  string(4) "2475"
  ["article_id"]=>
  string(4) "2475"
  [1]=>
  string(112) "Agile Therapeutics Resubmits New Drug Application (NDA) for its Transdermal Low-Dose Contraceptive Patch, Twirla"
  ["article_title"]=>
  string(112) "Agile Therapeutics Resubmits New Drug Application (NDA) for its Transdermal Low-Dose Contraceptive Patch, Twirla"
  [2]=>
  string(150) "PRINCETON, N.J., May 17, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced it has "
  ["short_description"]=>
  string(150) "PRINCETON, N.J., May 17, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced it has "
  [3]=>
  string(251) "PRINCETON, N.J., May 17, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced it has resubmitted to the U.S. Food and Drug Administration (FDA) the NDA for its lead product candidate,..."
  ["description"]=>
  string(251) "PRINCETON, N.J., May 17, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced it has resubmitted to the U.S. Food and Drug Administration (FDA) the NDA for its lead product candidate,..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "9"
  ["rss_id"]=>
  string(1) "9"
  [14]=>
  string(206) "https://www.drugs.com/nda/twirla_190517.html?utm_source=ddc&utm_medium=rss&utm_campaign=Agile+Therapeutics+Resubmits+New+Drug+Application+%28NDA%29+for+its+Transdermal+Low-Dose+Contraceptive+Patch%2C+Twirla"
  ["blog_url"]=>
  string(206) "https://www.drugs.com/nda/twirla_190517.html?utm_source=ddc&utm_medium=rss&utm_campaign=Agile+Therapeutics+Resubmits+New+Drug+Application+%28NDA%29+for+its+Transdermal+Low-Dose+Contraceptive+Patch%2C+Twirla"
  [15]=>
  string(19) "2019-05-17 14:05:15"
  ["add_date"]=>
  string(19) "2019-05-17 14:05:15"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:18:27"
  ["create_at"]=>
  string(19) "2019-05-23 14:18:27"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Agile Therapeutics Resubmits New Drug Application (NDA) for its Transdermal Low-Dose Contr

PRINCETON, N.J., May 17, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare co

array(40) {
  [0]=>
  string(4) "2469"
  ["article_id"]=>
  string(4) "2469"
  [1]=>
  string(102) "FDA Approves Gattex (teduglutide) for Children 1 Year of Age and Older With Short Bowel Syndrome (SBS)"
  ["article_title"]=>
  string(102) "FDA Approves Gattex (teduglutide) for Children 1 Year of Age and Older With Short Bowel Syndrome (SBS)"
  [2]=>
  string(150) "Lexington, MA, May 17, 2019 – Takeda Pharmaceuticals, U.S.A., Inc. (“Takeda”), announced today that the U.S. Food and Drug Administr"
  ["short_description"]=>
  string(150) "Lexington, MA, May 17, 2019 – Takeda Pharmaceuticals, U.S.A., Inc. (“Takeda”), announced today that the U.S. Food and Drug Administr"
  [3]=>
  string(249) "Lexington, MA, May 17, 2019 – Takeda Pharmaceuticals, U.S.A., Inc. (“Takeda”), announced today that the U.S. Food and Drug Administration (FDA) approved extending the indication of Gattex (teduglutide) for injection to pediatric..."
  ["description"]=>
  string(249) "Lexington, MA, May 17, 2019 – Takeda Pharmaceuticals, U.S.A., Inc. (“Takeda”), announced today that the U.S. Food and Drug Administration (FDA) approved extending the indication of Gattex (teduglutide) for injection to pediatric..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "8"
  ["rss_id"]=>
  string(1) "8"
  [14]=>
  string(277) "https://www.drugs.com/newdrugs/fda-approves-gattex-teduglutide-children-1-year-age-older-short-bowel-syndrome-sbs-4976.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Approves+Gattex+%28teduglutide%29+for+Children+1+Year+of+Age+and+Older+With+Short+Bowel+Syndrome+%28SBS%29"
  ["blog_url"]=>
  string(277) "https://www.drugs.com/newdrugs/fda-approves-gattex-teduglutide-children-1-year-age-older-short-bowel-syndrome-sbs-4976.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Approves+Gattex+%28teduglutide%29+for+Children+1+Year+of+Age+and+Older+With+Short+Bowel+Syndrome+%28SBS%29"
  [15]=>
  string(19) "2019-05-17 14:05:02"
  ["add_date"]=>
  string(19) "2019-05-17 14:05:02"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:18:26"
  ["create_at"]=>
  string(19) "2019-05-23 14:18:26"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

FDA Approves Gattex (teduglutide) for Children 1 Year of Age and Older With Short Bowel Sy

Lexington, MA, May 17, 2019 – Takeda Pharmaceuticals, U.S.A., Inc. (“Takeda”), announced today that th